Biologics & Biosimilar Clinical Trials | Amgen Biosimilars
CLEAR

Clinical Trials

Below is a list of Amgen-sponsored, disclosed clinical trials.

ABP 654 (Investigational biosimilar to STELARA® (ustekinumab))

Trials Status
A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis Recruitment Complete
A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis Active, not recruiting

ABP 938 (Investigational biosimilar to EYLEA® (aflibercept))

Trials Status
A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD] Active, not recruiting

ABP 959 (Investigational biosimilar to SOLIRIS® (eculizumab))

Trials Status
A Randomized, Double-Blind, Active-Controlled Phase 3 Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH) Recruitment Complete

STELARA is a trademark of Janssen Biotech, Inc.

EYLEA is a trademark of Regeneron Pharmaceuticals, Inc.

SOLIRIS is a trademark of Alexion Pharmaceuticals, Inc.

Previous: our pipeline Next: media releases